Among the 7 most common UL97 mutations encountered in ganciclovir-resistant clinical cytomegalovirus isolates, the associated cyclopropavir cross-resistance varies from insignificant (L595S) to substantial (M460I and H520Q) as determined by recombinant phenotyping. Mutations M460I and H520Q were preferentially selected in vitro under cyclopropavir and conferred 12-to 20-fold increases in 50% effective concentration (EC 50 ) values, while M460V, C592G, A594V, and C603W conferred 3-to 5-fold increases. Uncommon mutations M460T and C603R increased cyclopropavir EC 50 s by 8-to 10-fold.
As a major opportunistic pathogen in immunosuppressed individuals, especially transplant recipients, human cytomegalovirus (CMV) infection often requires prolonged antiviral prophylaxis or treatment (9) . Because the currently marketed drugs ganciclovir (GCV) (or its oral prodrug valganciclovir), foscarnet, and cidofovir can be limited by issues of tolerability and cross-resistance (10) , there are ongoing efforts to develop new antiviral options. Several Z-isomer methylenecyclopropane nucleoside analogs have shown potent in vitro anti-CMV activity (12) , particularly the compound cyclopropavir (CPV) (or ZSM-I-62, 5b [11] ), which had low cytotoxicity (8) and showed in vivo efficacy in an immunodeficient mouse model of human CMV infection (7) . CPV is an attractive candidate for clinical trials.
Similarly to GCV, initial phosphorylation by the viral UL97 kinase is required for the antiviral action of CPV (6) . Wellcharacterized (canonical) mutations in UL97 are found in GCV-resistant clinical strains, with one of the seven mutations M460V/I, H520Q, C592G, A594V, L595S, and C603W encountered in close to 90% of cases (10) . Other UL97 mutations confer various degrees of GCV resistance, while mutations in the UL54 DNA polymerase gene sometimes evolve to increase resistance to GCV and confer cross-resistance to cidofovir and/or foscarnet (10) . The extent of CPV cross-resistance conferred by GCV resistance mutations is not well defined. In this study, recombinant viruses containing various UL97 GCV resistance mutations were tested for CPV cross-resistance, and in vitro propagation of CMV under CPV was performed to see if mutations showing GCV cross-resistance were selected. Recombinant phenotyping to determine the effect of specific mutations on drug susceptibility is performed by site-specific mutagenesis of control laboratory strains of CMV followed by assay of the drug concentration required to reduce viral growth by 50% (EC 50 ). Recently this process has been facilitated by the cloning of control strains (e.g., AD169) as bacterial artificial chromosomes (BACs) and incorporation of reporter genes such as the secreted alkaline phosphatase (SEAP) gene for viral quantitation (3, 5) . Results from the updated assay system confirm earlier data showing that the canonical UL97 GCV resistance mutations each confer a 5-to 10-fold increase in GCV EC 50 , except C592G, which confers a 3-fold increase (3, 5, 10) . All of the recombinant viruses tested (Table 1) have been phenotyped for GCV susceptibility and published (3, 5) , except for T3362 (mutation M460I) and T3324 (mutation H520Q), which were constructed and assayed as previously described (3). The recombinant strains, representing several baseline genotypes, the canonical UL97 mutations, and the uncommon mutations M460T, C603R, and C603S, were assayed for their CPV EC 50 s by the same SEAP yield reduction assay as that used for GCV (3, 5) . CPV was provided by Microbiotix, Inc., and diluted into cell culture medium from a 10 mM stock solution in dimethyl sulfoxide (DMSO).
CPV susceptibility data (Table 1) showed that baseline CMV strains had CPV EC 50 values of 0.20 to 0.26 M, which are 4-to 5-fold less than those for GCV (3), consistent with earlier data for CPV (11) . Among the GCV-resistant mutants, CPV cross-resistance varied from insignificant (L595S) to substantial (M460I/T, H520Q, and C603R), with the latter mutations conferring 8-to 20-fold increases in CPV EC 50 . Among the three most common GCV resistance mutations, A594V, L595S, and M460V (10), there was a 4-to 5-fold increase in CPV EC 50 for two of them.
Previous information on CPV-GCV cross-resistance is hard to evaluate because of its preliminary nature. CPV was reported to have significant activity against GCV-resistant strains (8) , but the genotypes of the tested strains were not specified; it is unlikely that mutation M460I or H520Q was represented. A conference abstract reported that a UL97 M460I-C603Y double mutant, selected under a related compound, synadenol, was cross resistant to CPV and that the mutations individually conferred 6-to 8-fold-increased CPV resistance (2) . This is comparable to information in Table 1 , where different mutations at codon 603 confer various levels of CPV resistance. The M460I-C603Y double mutant apparently showed 13-fold and 11-fold increases in EC 50 for CPV and GCV, respectively (12) . Another conference abstract (1) reported that CPV selected for a frameshift mutation in UL97 that truncated the expressed protein at residue 168, far upstream of residues composing critical kinase domains. Mutations that abrogate normal biological UL97 kinase function are not expected in clinical isolates, based on experience with GCV, because of their associated viral growth defect (10) .
Mutations selected in vitro under CPV were assessed by propagating an error-prone exonuclease mutant containing UL54 mutation D413A (T2294 or a more recent BACcloned strain, T3360). This mutant shows an accelerated evolution of resistance mutations under drug (4) . Using the same methods previously described (4), T2294 or T3360 was serially propagated for 15 passages under CPV starting at 0.2 M and escalating to a final concentration of 2 to 4 M. Infected cell extracts were checked at intervals for the presence of UL97 mutations. Table 2 shows the outcome of 18 experiments. Mutations became detectable at 7 passages; by passages 13 to 15, a mutation had developed in all of the cultures propagated under CPV. M460I was the most common, appearing in 12 of the cultures, followed by H520Q in 7 cultures, 2 of which contained both M460I and H520Q. In the latter 2 cases, each mutation was present as a mixture with the wild-type configuration. The unusual mutation C603R was selected in one instance. These in vitro selection results support the relevance of the cross-resistance data in Table 1 , although the exact frequency of specific resistance mutations in posttreatment clinical isolates may differ from those found in vitro (10) .
In conclusion, UL97 mutations M460I and H520Q have a major role in CPV resistance and GCV cross-resistance. The relative potency and low toxicity of CPV suggest that meaningful antiviral activity may be retained against some common GCV-resistant UL97 mutants ( Table 1) that show less than a 5-fold increase in CPV EC 50 . However, such mutations may favor the subsequent selection of other mutations, including those in the UL54 DNA polymerase gene, that result in higher levels of CPV resistance. This requires further study. 
